Univest
Univest
  • Markets

Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals

  • November 19, 2026
  • Posted by: Chaitanya Auti
  • Category: Best Stocks
No Comments
Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals

Table of Contents

Toggle
  • Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals
    • How Much Has the Laurus Labs Share Price Returned in 3 Years?
    • Laurus Labs vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared
    • Valuation and Quality Compared
    • What Is Driving the Laurus Labs Stock?
    • How the Established Players Stack Up
    • What Should Investors Track Next?
    • How to Compare Pharma Stocks Yourself
    • An API and CDMO Maker Beside Three Pharma Names
    • Frequently Asked Questions
      • What is the Laurus Labs share price today?
      • What is the 3-year CAGR of the Laurus Labs stock?
      • Is Laurus Labs better than Lupin?
      • What does Laurus Labs do?
      • Is the Laurus Labs stock debt free?
      • Is Laurus Labs expensive compared with the industry?
      • Which pharma stock gave the highest return in 3 years?
      • How do I calculate CAGR for a stock?

Laurus Labs Share Price: 84.5% CAGR in 3 Years as the Hyderabad-Based API Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals

Laurus Labs previous close Rs 2,322.50. 3-year CAGR 84.5%. Up 6.3x since 17 Nov 2023. ROE 22.11%. Market cap Rs 1,25,461 crore.

Quick Answer

The Laurus Labs share price closed at Rs 2,322.50 on 18 November 2026, a compounded annual return of 84.5% over three years. That compares with Zydus Lifesciences at 23.6%, Lupin at 18.1% and Glenmark Pharmaceuticals at 50.5%. The company has a market cap of Rs 1,25,461 crore and a P/E of 94.16 against an industry P/E of 40.12.

The Laurus Labs share price closed at Rs 2,322.50 on 18 November 2026 and has compounded at 84.5% a year over three years, which means the stock has gained about 6.3 times and leads the four pharma companies compared here. Laurus Labs, based in Hyderabad, makes active pharmaceutical ingredients, finished formulations and contract development services.

This article places that run beside Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals. We calculate the three-year CAGR for all four and set the results next to market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.

Click Here – Get Free Investment Predictions

How Much Has the Laurus Labs Share Price Returned in 3 Years?

The Laurus Labs stock closed at Rs 369.85 on 17 November 2023 and at Rs 2,322.50 on 18 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 6.28 lakh, which is a CAGR of 84.5%. This is a price return and leaves out dividends.

CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Laurus Labs can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.

A company that supplies ingredients and development services earns on volumes and long term supply contracts, so the price follows capacity and customer wins. The Laurus Labs share price shows how fast such a business can rerate when new segments scale.

Laurus Labs vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared

The table ranks the companies by three-year CAGR. Prices on 17 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 18 November 2026.

Company Close on 17 Nov 2023 Previous close (18 Nov 2026) Price multiple 3-year CAGR
Laurus Labs Rs 369.85 Rs 2,322.50 6.3x 84.5%
Glenmark Pharmaceuticals Rs 775.95 Rs 2,646.10 3.4x 50.5%
Zydus Lifesciences Rs 636.55 Rs 1,202.00 1.9x 23.6%
Lupin Rs 1,196.30 Rs 1,971.90 1.6x 18.1%

The Laurus Labs stock leads the group at 84.5%, followed by Glenmark Pharmaceuticals at 50.5%, Zydus Lifesciences at 23.6% and Lupin at 18.1%. By market cap the company ranks first of the four at Rs 1,25,461 crore. Laurus Labs is the largest of the four by market cap.

Look at the Laurus Labs share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.

Valuation and Quality Compared

Company Market cap P/E Industry P/E ROE Debt to equity
Laurus Labs Rs 1,25,461 crore 94.16 40.12 22.11% 0.43
Zydus Lifesciences Rs 1,19,202 crore 27.71 40.12 15.10% 0.50
Lupin Rs 90,039 crore 17.24 40.12 21.65% 0.26
Glenmark Pharmaceuticals Rs 74,931 crore 51.63 40.12 18.07% 0.13

By market cap, Laurus Labs is the largest of the group at Rs 1,25,461 crore, which gives it the scale advantage over Zydus Lifesciences, Lupin, Glenmark Pharmaceuticals. On earnings, Laurus Labs shares trade at a P/E of 94.16 against an industry P/E of 40.12, a premium of about 135%, which signals that the market expects faster earnings growth. Peer multiples are Zydus Lifesciences at 27.71, Lupin at 17.24 and Glenmark Pharmaceuticals at 51.63.

Return on equity is 22.11% for the Laurus Labs stock, which ranks first among the four, and debt to equity stands at 0.43. Trailing EPS is Rs 24.66. Laurus Labs trades at a P/E of 94.16 against an industry P/E of 40.12, with a price to book of 20.70. Its ROE of 22.11% is the highest in the group.

What Is Driving the Laurus Labs Stock?

Laurus earns revenue from active ingredients for antiretroviral and other medicines, finished formulations, and a contract development business that works with global drug makers. New segments add to its base over time.

The company earns an ROE of 22.11%, which is the highest in the group, and carries a debt to equity of 0.43. Its P/E of 94.16 sits well above the industry P/E of 40.12.

Investors who follow the Laurus Labs share price usually track capacity additions, contract development wins, margin on ingredients and progress in newer segments.

How the Established Players Stack Up

Zydus Lifesciences is an Ahmedabad-based drug maker with generics, branded medicines and a vaccines business. It compounded at 23.6% a year, on a market cap of Rs 1,19,202 crore and an ROE of 15.10%.

Lupin is a Mumbai-based drug maker with a strong presence in respiratory and cardiovascular medicines. It compounded at 18.1% a year, on a market cap of Rs 90,039 crore and an ROE of 21.65%.

Glenmark Pharmaceuticals is a Mumbai-based drug maker with a presence in dermatology and respiratory therapies. It compounded at 50.5% a year, on a market cap of Rs 74,931 crore and an ROE of 18.07%.

What Should Investors Track Next?

Three things are worth watching on the Laurus Labs share price. First, growth in its contract development business. Second, margin on ingredients and formulations. Third, capacity additions and utilisation.

At a P/E of 94.16 the stock trades well above the industry P/E of 40.12, so expectations are already high. Order timing can move results, so follow each result closely.

Check the Univest Screener for live fundamentals of pharma stocks

How to Compare Pharma Stocks Yourself

You can repeat this exercise for any pair of stocks, including the Laurus Labs stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.

A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Laurus Labs share price, the same four checks give a more complete picture than price alone.

Download the Univest iOS App or Univest Android App to track the Laurus Labs share price and compare pharma stocks live.

An API and CDMO Maker Beside Three Pharma Names

The Laurus Labs share price compounded at 84.5% a year over three years, against 50.5% for Glenmark, 23.6% for Zydus and 18.1% for Lupin. Its ROE of 22.11% is the highest of the four.

Laurus Labs brings the fastest return, Laurus Labs brings the highest ROE and Lupin brings the lowest P/E. Laurus Labs offers an ingredient and development focus, which the other three mix with branded medicines.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the Laurus Labs share price today?

Ans. Laurus Labs closed at Rs 2,322.50 on 18 November 2026, according to NSE data. It has a market cap of Rs 1,25,461 crore and a P/E of 94.16. Check live quotes before acting, as prices change every trading day.

What is the 3-year CAGR of the Laurus Labs stock?

Ans. Laurus Labs delivered a price CAGR of 84.5% over three years, moving from Rs 369.85 on 17 November 2023 to Rs 2,322.50 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.

Is Laurus Labs better than Lupin?

Ans. Laurus Labs delivered the higher three-year CAGR at 84.5% against 18.1% for Lupin. Laurus Labs has the larger market cap at Rs 1,25,461 crore against Rs 90,039 crore for Lupin. Laurus Labs earns the higher ROE at 22.11% against 21.65%. Lupin trades at the lower P/E of 17.24 against 94.16. The better choice depends on whether you weigh recent return, size, profitability or valuation most.

What does Laurus Labs do?

Ans. Laurus Labs Limited is a Hyderabad-based pharmaceutical company that makes active pharmaceutical ingredients and finished formulations and offers contract development and manufacturing services.

Is the Laurus Labs stock debt free?

Ans. The debt to equity ratio of the Laurus Labs stock is 0.43 and its return on equity is 22.11%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.

Is Laurus Labs expensive compared with the industry?

Ans. Laurus Labs trades at a P/E of 94.16 against an industry P/E of 40.12. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.

Which pharma stock gave the highest return in 3 years?

Ans. Among the companies compared here, Laurus Labs delivered the highest three-year CAGR at 84.5%, followed by Glenmark Pharmaceuticals at 50.5%. Past returns do not guarantee future performance.

How do I calculate CAGR for a stock?

Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.



laurus labs share price Laurus Labs stock Laurus Labs vs Lupin pharma stocks 3 year return

Leave a Reply Cancel reply